NCT00209326已完成2 期
A Randomised, Double-blind, Parallel Group, Dose-ranging, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of Four Different Single Bolus Intravenous Doses of FE200440 (0.3, 1, 3, 10 mg) and Placebo on Stopping Preterm Labour and Uterine Contractions in Pregnant Women With Advanced Gestational Age
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 163
- 试验地点
- 34
研究概览
简要总结
• To determine the effects of four different single bolus doses of FE200440 administered intravenously on stopping preterm labour compared to placebo in pregnant women with advanced gestational age
详细描述
- To determine the effects of four different single bolus doses of FE200440 administered intravenously on stopping preterm labour compared to placebo in pregnant women with advanced gestational age
- To establish the effects of four different single bolus doses of FE200440 administered intravenously on uterine contractions compared to placebo
- To evaluate the effects of four different single bolus doses of FE200440 administered intravenously on labour progression compared to placebo
- To establish the dose-response curve of single bolus doses of FE200440 administered intravenously in terms of time to delivery, uterine contractions and labour progression
- To determine the duration of action of four different single bolus doses of FE200440 administered intravenously in terms of time to delivery, uterine contractions and labour progression
- To establish the pharmacokinetic parameters of FE200440 after single bolus intravenous administration
- To determine the relation between plasma concentrations of FE200440 and uterine contractions and labour progression
- To compare the maternal, fetal and infant safety profile after intravenous administration of four different single bolus doses of FE200440 and placebo
- To evaluate the impact of four different single bolus doses of FE200440 administered intravenously on delivery outcome, postpartum events and lactation
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form, prior to screening evaluations
- •Mother and fetus in good general health
- •Pregnant women age ≥ 18 years
- •Gestational age (verified by early ultrasound or if an ultrasound is not available by Last Menstrual Period) between 34 weeks + 0 days and 35 weeks + 6 days (both days inclusive)
- •At randomisation, there must be 6 or more uterine contractions of at least 30 seconds duration during a 30 minutes interval
- •At randomisation, the cervical length must be ≤ 15 mm (by transvaginal ultrasound)
- •At randomisation, the cervical dilatation must be >1 cm and <4 cm (by vaginal examination
排除标准
- •Contraindications for the mother or the fetus to stop labour, including
- •clinical suspicion of abruptio placenta
- •known or suspected infection (e.g. urinary tract infection, chorioamnionitis)
- •Controlled or uncontrolled diabetes mellitus (pre-gestational or gestational)
- •Eclampsia or severe preeclampsia in the current pregnancy
- •Previous major uterine surgery (e.g. myomectomy for leiomyomas), congenital uterine abnormalities, large leiomyomas, or retained intrauterine device
- •Rupture of membrane in the current pregnancy
- •Placenta praevia in the current pregnancy
- •Oligohydramnios or polyhydramnios in the current pregnancy defined as amniotic fluid index (AFI) below 7.2 cm or above 27.8 cm
- •Fetal weight (based on ultrasound) outside the ± 2SD limits provided in Appendix B
- •Use of cervical cerclage in the current pregnancy
- •Current multiple pregnancy
- •Fetal death in utero in previous or current pregnancy
- •Fetus with known or suspected abnormal karyotype or major malformations in the current pregnancy
- •Abnormal fetal heart rate which the Investigator judges to reflect fetal distress
- •Treatment with nifedipine, non-steroidal anti-inflammatory agents (NSAIDs) or intravenously administered magnesium sulphate for contractions during the current pregnancy or treatment with beta-mimetics, atosiban or progesterone within the last 7 days prior to randomisation
- •Treatment with anticoagulation or fibrinolytic therapies prior to screening, or known or suspected or past history of thromboembolic disorders
- •Known, suspected or past history of hypocoagulability or coagulation deficiency conditions
- •Known or suspected hemoglobinopathies
- •Use of any investigational drug during the current pregnancy
- •Known, suspected or past history (last 12 months) of alcohol or drug abuse
- •Known hypersensitivity to the active ingredient or to any of its excipients
研究者
研究点 (34)
Loading locations...
相似试验
已完成
1 期
A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's DiseaseAlzheimer's DiseaseNCT00455000Pfizer37
已完成
1 期
Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous FL058 Administered in Healthy Subjects(SAD/MAD)HealthyNCT05055687Qilu Pharmaceutical Co., Ltd.20
终止
4 期
Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion SettingComplicated Skin or Skin Structure InfectionNCT01175707Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)80
已完成
1 期
A Multiple Dose Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04457845 in Healthy VolunteersAcute PainChronic PainNCT00836082Pfizer41
已完成
2 期
Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine ContractionsInfertilityNCT01723982Ferring Pharmaceuticals256